Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail for each project, over and over again. These projects can take up to five years before reaching full operation and have an obsolescence risk because technology and solutions have often moved on by the time the project is completed. Even an agile project can take significant time to complete due to the number of inherent iterative design loops.

These traditional projects can be expensive to build and modify, and may be inflexible if they have to change to accommodate new products. A new approach and mindset are needed to change the way that manufacturing facilities are designed and constructed.

 

The approach includes creating design modules that encompass predefined solutions for equipment operations, accessory support areas, as well as space modules for circulation, access and component staging.

The BioPhorum Technology Roadmap Standard Facility Design working group has, therefore, stepped up to produce the Improving the Biomanufacturing Facility Lifecycle using a Standardized, Modular Design and Construction Approach white paper.

“The paper sets out to influence and align manufacturers, consulting engineers, suppliers and constructors around common terminology and definitions, as well as project execution methods that apply to the design and construction of biopharmaceutical facilities,” said Doug DeVeny, Global Technical Lead, Architecture/HVAC, Pharma Global Engineering at Genentech. “To reduce project timelines and costs, as well as increase the flexibility and lifecycle adaptability of facilities, moving towards more standardized, modular design and construction solutions is needed to meet the demands of the biopharmaceutical market.”

The paper proposes a standardized design approach, along with an example facility concept for a 2 x 2,000L monoclonal antibody (mAb) drug substance manufacturing facility, primarily utilizing a single-use technology platform.

The example solution can be used as a template for similar 2,000L-scale mAb projects or as a basis for new standardized facility templates for other applications. It discusses how a modular design approach may be realized using various construction methods – including traditional stick-built, prefabricated and skid assemblies, modular cleanrooms or complete modular building units – without needing major design reconfiguration.

The paper creates a vision of how a future biopharmaceutical manufacturing facility might look. So instead of starting with a blank piece of paper every time a new facility is needed, it recommends looking to standardization and a more modular approach to design and building. This would have many benefits, including faster use of a new facility, deferred capital expenditure, more rapid product launches as well as increasing a facility’s lifecycle by adapting it for different needs.

“The main benefit of the paper is that it highlights the distinction between modular design and modular construction, which is not well understood within the industry,” said Austin Lock, Technical Director & Deputy Pharmaceutical Sector Director at PM Group. “By using a single-use mAbs facility as an example, the paper identifies how a methodology, which incorporates both modular design and modular construction as core fundamentals, can be used to deliver a standard manufacturing facility, enabling significant benefits such a faster speed to market and reduced CAPEX.”

Publishing the white paper is the end point of a successful process, from the whole collaboration and overcoming confusion about terminology, to demonstrating that a modular and mobile facility is a viable proposition. One of the real achievements is that engineering firms have engaged in the process and not seen it as a threat to their design services; they can see how using it means they can provide better value to their clients.

The next step for the team is to consider the needs of cell and gene therapy facilities while applying the principles from the paper to develop another example of a facility concept. The team will also provide guidance on how to apply these standards in the set up of catalogs that can enable manufacturers to more easily and quickly select the components needed to design and build a facility.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Proactive prioritization: a new tool for assessing raw material risk

The Raw Material Risk Management workstream has launched a new, raw material risk assessment tool aimed at helping industry identify and prioritize around the challenging[...]

Read More
How well can you handle SUS changes?  Take our surveys and see

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Decision tree to support alignment of risk assessment for changes to single-use biomanufacturing systems

The BioPhorum single use change notification team has been working on developing and standardizing best practice for single use change notification since 2015.  The challenges[...]

Read More
PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
Read More
Driving the evolution of secondary packaging

How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
BioPhorum’s Maturity Assessment Tool gains momentum
Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More
PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
Read More
BioPhorum’s Maturity Assessment Tool gains momentum
Read More
Driving the evolution of secondary packaging

How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

Read More